Stock Market News5 months Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek Zacks
The FDA’s nod is based on late-stage data, which show that treatment with VRTX’s Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
5 months Jazz Pharmaceuticals: Should Sing A Better Tune In 2025 Seeking Alpha
5 months Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? Zacks
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
5 months Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval Seeking Alpha
5 months Is Recursion Pharmaceuticals Stock a Millionaire Maker? Yahoo Finance
5 months Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein Yahoo Finance
5 months Vertex Wins An Early Approval; Why It Might Not Move Vertex’s Beleaguered Stock Investor's Business Daily
The Food and Drug Administration signed off on Vertex Pharmaceuticals’ next-generation triple drug for cystic fibrosis late Friday.
The post Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock appeared first on Investor…
5 months Ironwood Pharmaceuticals shares surge on competitor’s woes Investing.com
5 months Rhythm Pharmaceuticals’ Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential Yahoo Finance
5 months Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity Seeking Alpha
5 months VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo Zacks
Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
5 months Cramer’s Mad Dash: Vertex Pharmaceuticals YouTube
5 months Ionis Gets FDA Approval for Rare Disease Drug Tryngolza Zacks
The FDA’s nod to IONS’ Tryngolza makes it the first approved treatment for FCS. It is also the company’s first wholly-owned drug to receive marketing approval.
5 months Cramer’s Stop Trading: Vertex Pharmaceuticals YouTube
5 months Vertex Non-Opioid Drug Doesn’t Best Placebo In Back Pain Study. The Stock Is Plunging. Investor's Business Daily
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
The post Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging….
5 months Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting Seeking Alpha
5 months REGN’s Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study Zacks
Regeneron’s phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
5 months Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It Zacks
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock’s prospects.
5 months SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study Zacks
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn’s disease indications.
5 months Corvus Pharmaceuticals stock rebounds on positive trial results Investing.com
5 months Stocks making the biggest moves midday: Pfizer, Broadcom, Teva Pharmaceuticals and more CNBC
These are the stocks posting the largest moves in midday trading.
5 months NVS vs. LLY: Which Stock Should Value Investors Buy Now? Zacks
NVS vs. LLY: Which Stock Is the Better Value Option?
5 months 4 Big Drug Stocks That May Continue to Outperform in 2025 Zacks
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
5 months Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know Zacks
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
5 months Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today Zacks
Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
5 months BMY vs. VRTX: Which Stock Is the Better Value Option? Zacks
BMY vs. VRTX: Which Stock Is the Better Value Option?
5 months Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison’s Top 2 Picks Seeking Alpha
5 months Inovio Pharmaceuticals: The Dangerous Allure Of A Falling Knife Seeking Alpha
5 months Regeneron Down 15.5% Year to Date: How to Play the Stock? Zacks
REGN’s lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
5 months Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? Zacks
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
5 months Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? Zacks
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
5 months Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable Seeking Alpha
5 months Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low Seeking Alpha
5 months Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy Seeking Alpha
5 months How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% Zacks
The mean of analysts’ price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
5 months Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.
5 months Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations Seeking Alpha
5 months Here’s Why Agios Stock Plummeted More Than 20% on Monday Zacks
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
5 months Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options Zacks
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
5 months Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? Zacks
Sector ETF report for PJP
5 months BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy Seeking Alpha
5 months Agios Crashes 21% After A Surprise Side Effect Hammered Its ‘Very Safe’ Drug Investor's Business Daily
Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company’s thalassemia treatment, mitapivat.
The post Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug appeared first on I…
5 months Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future Seeking Alpha
5 months Rhythm Pharmaceuticals: A Key Year Ahead Seeking Alpha
5 months Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? Zacks
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
5 months Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound? Zacks
Acadia (ACAD) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
5 months Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand Zacks
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
5 months Down -54.05% in 4 Weeks, Here’s Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround Zacks
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
5 months Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript) Seeking Alpha
5 months Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? Zacks
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
The Stock Market News
The Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live qoute and chart technical analysis, opinion, price forecast on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.